Covered recipient · General Payments record
DARVY LEE MANN
Allopathic & Osteopathic Physicians Pediatrics
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
Saved only in this browser. No account or alerts.
General Payments · PY2022 · Entire year
$300.49
20 records · 0 disputed
“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”
— Centers for Medicare & Medicaid Services, Open Payments
A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.
These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
How these totals are calculated
- This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Methodology & Data — sourcing, labeling, and limitations.
Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗
By nature of payment
PY2022 · entire year · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $300.49 | 20 |
By paying entity
PY2022 · entire year · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| Corium, LLC | $141.80 | 11 |
| Ironshore Pharmaceuticals Inc. | $66.36 | 4 |
| Merck Sharp & Dohme LLC | $59.68 | 3 |
| CMP Pharma, Inc. | $16.63 | 1 |
| kaleo, Inc. | $16.02 | 1 |
Page 1 of 1; records 1–20 of 20 matching records. This page contains 20 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.
IndustryPayments · General Payments
DARVY LEE MANN
NPI 1275832479 · CMS profile ID 1169194
Allopathic & Osteopathic Physicians / Pediatrics
LONGVIEW, TX
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types
Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00
Page 1 of 1; records 1–20 of 20 matching records. This page contains 20 records (maximum 50), not the full filtered export.
Filtered page: https://industrypayments.org/provider/npi-1275832479?year=2022&recipient=provider#records-h
CMS source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c
Cite these filtered records
The citation includes this program year, filters, data edition, and page of results.
- Plain
- DARVY LEE MANN, NPI 1275832479, CMS profile ID 1169194. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–20 of 20 matching records. This page contains 20 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1275832479?year=2022&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
- APA 7
- IndustryPayments. (2026). DARVY LEE MANN, NPI 1275832479, CMS profile ID 1169194. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–20 of 20 matching records. This page contains 20 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1275832479?year=2022&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
- Bluebook
- DARVY LEE MANN, NPI 1275832479, CMS profile ID 1169194, IndustryPayments, General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–20 of 20 matching records. This page contains 20 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c. https://industrypayments.org/provider/npi-1275832479?year=2022&recipient=provider#records-h.
Centers for Medicare & Medicaid Services, Open Payments
Citation formats are provided for reference; check the requirements of your publication.
Payment records · PY2022
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
General Payments · PY2022 · Physicians and non-physician practitioners · CMS publication 2026-06-30
20 matching records · $300.49 reported total · 0 disputed
Nature of payment: All payment types
Records imported here (UTC).
CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.
Showing records 1–20 of 20.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Publication flags | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|---|
| Merck Sharp & Dohme LLC | $22.06 | 12/05/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 944736465 | CMS |
| Corium, LLC | $17.16 | 12/01/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 924813793 | CMS |
| Merck Sharp & Dohme LLC | $18.18 | 11/03/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 944738361 | CMS |
| Corium, LLC | $6.39 | 10/31/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 924813791 | CMS |
| Corium, LLC | $3.36 | 10/06/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 924813787 | CMS |
| Corium, LLC | $7.84 | 10/06/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 924813789 | CMS |
| Corium, LLC | $18.33 | 09/13/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 924813785 | CMS |
| Ironshore Pharmaceuticals Inc. | $12.08 | 09/02/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 958778613 | CMS |
| Corium, LLC | $8.66 | 08/25/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 924813783 | CMS |
| Corium, LLC | $11.21 | 08/17/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 924813781 | CMS |
| Corium, LLC | $17.27 | 08/12/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 924813779 | CMS |
| CMP Pharma, Inc. | $16.63 | 07/28/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 932177149 | CMS |
| kaleo, Inc. | $16.02 | 05/23/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 941013489 | CMS |
| Corium, LLC | $22.85 | 05/18/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 924813777 | CMS |
| Ironshore Pharmaceuticals Inc. | $15.76 | 05/13/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 958778617 | CMS |
| Ironshore Pharmaceuticals Inc. | $13.57 | 03/29/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 958778615 | CMS |
| Merck Sharp & Dohme LLC | $19.44 | 03/08/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 944738667 | CMS |
| Corium, LLC | $11.70 | 02/14/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 924813775 | CMS |
| Corium, LLC | $17.03 | 01/26/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 924813773 | CMS |
| Ironshore Pharmaceuticals Inc. | $24.95 | 01/07/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 958778619 | CMS |
By program year
All program years on this page · sorted by year
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-06-30
- Program years on this page
- 2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
- Source files
- Dataset page · Bulk file · PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024 , PY2025
- Generated from
- OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.
Research Payments
One row per program year and role, newest year first · amounts for the two roles are never added together
| Program year | Role | Amount | Records |
|---|---|---|---|
| PY2025 | Principal investigator | $59,716.71 | 24 |
| PY2024 | Principal investigator | $61,020.88 | 14 |
| PY2023 | Principal investigator | $72,104.63 | 22 |
| PY2022 | Principal investigator | $325,094.46 | 64 |
| PY2021 | Principal investigator | $289,713.17 | 73 |
| PY2020 | Principal investigator | $296,305.70 | 95 |
| PY2019 | Principal investigator | $139,835.21 | 55 |
Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.
“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”
— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224
Research Payments records · PY2021
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
73 records in PY2021
| Role | Paying entity | Amount | Date | Recipient | Study | Dispute status | Published | Record ID |
|---|---|---|---|---|---|---|---|---|
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $348.31 | 12/31/2021 | Non-covered Recipient Entity ASSOCIATED CLINICIANS OF EAST TEXAS | A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of MEDI8897, a Monoclonal Antibody With an Extended Half-life Against Respiratory Syncytial Virus, in Healthy Late Preterm and Term Infants (MELODY) | No dispute reported | 06/30/2026 | 826484797 |
| Principal investigator 1 | Merck Sharp & Dohme Corporation | $24,146.48 | 12/31/2021 | Non-covered Recipient Entity DCOL CENTER FOR CLINICAL RESEARCH | A Phase 2b,3 Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of MK-1654 in Healthy Pre-Term and Full-Term Infants | No dispute reported | 06/30/2026 | 848741199 |
| Principal investigator 1 | Merck Sharp & Dohme Corporation | $437.73 | 12/31/2021 | Non-covered Recipient Entity DCOL CENTER FOR CLINICAL RESEARCH | A Phase 2b,3 Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of MK-1654 in Healthy Pre-Term and Full-Term Infants | No dispute reported | 06/30/2026 | 848741201 |
| Principal investigator 1 | Merck Sharp & Dohme Corporation | $46,413.06 | 12/31/2021 | Non-covered Recipient Entity DCOL CENTER FOR CLINICAL RESEARCH | A Phase 3, Multicenter, Randomized, Double-blind, Active-Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of a 4-dose Regimen of V114 in Healthy Infants PNEU-PED | No dispute reported | 06/30/2026 | 848763373 |
| Principal investigator 1 | PFIZER INC. | $4,562.74 | 12/23/2021 | Non-covered Recipient Entity Associated Clinicians of East Texas PLLC | A PHASE 3 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN HEALTHY INFANTS | No dispute reported | 06/30/2026 | 832567711 |
| Principal investigator 1 | Merck Sharp & Dohme Corporation | $13,662.30 | 12/20/2021 | Non-covered Recipient Entity DCOL CENTER FOR CLINICAL RESEARCH | A Phase 2b,3 Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of MK-1654 in Healthy Pre-Term and Full-Term Infants | No dispute reported | 06/30/2026 | 848741197 |
| Principal investigator 1 | SANOFI PASTEUR INC. | $1,373.00 | 12/17/2021 | Non-covered Recipient Entity Associated Clinicians Of East Texas | Safety and Immunogenicity of a Pneumococcal Conjugate Vaccine When Administered Concomitantly With Routine Pediatric Vaccines in Healthy Toddlers and Infants | No dispute reported | 06/30/2026 | 838375977 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $667.94 | 12/14/2021 | Non-covered Recipient Entity ASSOCIATED CLINICIANS OF EAST TEXAS PLLC | A PHASE III, RANDOMIZED, CONTROLLED, OBSERVER-BLIND STUDY TO EVALUATE | No dispute reported | 06/30/2026 | 965538795 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $968.52 | 12/08/2021 | Non-covered Recipient Entity ASSOCIATED CLINICIANS OF EAST TEXAS PLLC | A PHASE III, RANDOMIZED, CONTROLLED, OBSERVER-BLIND STUDY TO EVALUATE | No dispute reported | 06/30/2026 | 965538797 |
| Principal investigator 1 | PFIZER INC. | $4,189.67 | 12/07/2021 | Non-covered Recipient Entity Associated Clinicians of East Texas PLLC | A PHASE 3 RANDOMIZED DOUBLEBLINDED PLACEBOCONTROLLED TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF A RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN INFANTS BORN TO WOMEN VACCINATED DURING PREGNANCY | No dispute reported | 06/30/2026 | 832566129 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $3,129.35 | 12/02/2021 | Non-covered Recipient Entity ASSOCIATED CLINICIANS OF EAST TEXAS PLLC | A PHASE III, RANDOMIZED, CONTROLLED, OBSERVER-BLIND STUDY TO EVALUATE | No dispute reported | 06/30/2026 | 965538799 |
| Principal investigator 1 | PFIZER INC. | $3,718.78 | 11/24/2021 | Non-covered Recipient Entity Associated Clinicians of East Texas PLLC | A PHASE 3 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN HEALTHY INFANTS | No dispute reported | 06/30/2026 | 832695915 |
| Principal investigator 1 | PFIZER INC. | $7,878.98 | 11/23/2021 | Non-covered Recipient Entity Associated Clinicians of East Texas PLLC | A PHASE 3 RANDOMIZED DOUBLEBLINDED PLACEBOCONTROLLED TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF A RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN INFANTS BORN TO WOMEN VACCINATED DURING PREGNANCY | No dispute reported | 06/30/2026 | 832780780 |
| Principal investigator 1 | Merck Sharp & Dohme Corporation | $12,945.00 | 11/17/2021 | Non-covered Recipient Entity DCOL CENTER FOR CLINICAL RESEARCH | A Phase 3, Multicenter, Randomized, Double-blind, Active-Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of a 4-dose Regimen of V114 in Healthy Infants PNEU-PED | No dispute reported | 06/30/2026 | 848763367 |
| Principal investigator 1 | SANOFI PASTEUR INC. | $2,239.00 | 11/10/2021 | Non-covered Recipient Entity Associated Clinicians Of East Texas | PSK0008 Safety and Immunogenicity of a Pneumococcal Conjugate Vaccine (PCV) when Administered Concomitantly with Routine Pediatric Vaccines in Healthy Toddlers and Infants | No dispute reported | 06/30/2026 | 838375969 |
| Principal investigator 1 | PFIZER INC. | $3,584.17 | 11/05/2021 | Non-covered Recipient Entity Associated Clinicians of East Texas PLLC | A PHASE 3 RANDOMIZED DOUBLEBLINDED PLACEBOCONTROLLED TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF A RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN INFANTS BORN TO WOMEN VACCINATED DURING PREGNANCY | No dispute reported | 06/30/2026 | 832758279 |
| Principal investigator 1 | PFIZER INC. | $300.00 | 11/05/2021 | Non-covered Recipient Entity Associated Clinicians of East Texas PLLC | A PHASE 3 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN HEALTHY INFANTS | No dispute reported | 06/30/2026 | 832782663 |
| Principal investigator 1 | PFIZER INC. | $2,949.83 | 10/21/2021 | Non-covered Recipient Entity Associated Clinicians of East Texas PLLC | A PHASE 3 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN HEALTHY INFANTS | No dispute reported | 06/30/2026 | 832758289 |
| Principal investigator 1 | PFIZER INC. | $577.01 | 10/21/2021 | Non-covered Recipient Entity Associated Clinicians of East Texas PLLC | A PHASE 3 RANDOMIZED DOUBLEBLINDED PLACEBOCONTROLLED TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF A RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN INFANTS BORN TO WOMEN VACCINATED DURING PREGNANCY | No dispute reported | 06/30/2026 | 832768411 |
| Principal investigator 1 | PFIZER INC. | $98.91 | 10/09/2021 | Non-covered Recipient Entity Associated Clinicians of East Texas PLLC | A PHASE 3 RANDOMIZED DOUBLEBLINDED PLACEBOCONTROLLED TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF A RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN INFANTS BORN TO WOMEN VACCINATED DURING PREGNANCY | No dispute reported | 06/30/2026 | 832783635 |
| Principal investigator 1 | PFIZER INC. | $4,908.11 | 10/08/2021 | Non-covered Recipient Entity Associated Clinicians of East Texas PLLC | A PHASE 3 RANDOMIZED DOUBLEBLINDED PLACEBOCONTROLLED TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF A RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN INFANTS BORN TO WOMEN VACCINATED DURING PREGNANCY | No dispute reported | 06/30/2026 | 832838201 |
| Principal investigator 1 | SANOFI PASTEUR INC. | $2,239.00 | 10/06/2021 | Non-covered Recipient Entity Associated Clinicians Of East Texas | PSK0008 Safety and Immunogenicity of a Pneumococcal Conjugate Vaccine (PCV) when Administered Concomitantly with Routine Pediatric Vaccines in Healthy Toddlers and Infants | No dispute reported | 06/30/2026 | 838375963 |
| Principal investigator 1 | PFIZER INC. | $5,832.80 | 09/22/2021 | Non-covered Recipient Entity Associated Clinicians of East Texas PLLC | A PHASE 3 RANDOMIZED DOUBLEBLINDED PLACEBOCONTROLLED TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF A RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN INFANTS BORN TO WOMEN VACCINATED DURING PREGNANCY | No dispute reported | 06/30/2026 | 832733427 |
| Principal investigator 1 | PFIZER INC. | $1,859.39 | 09/22/2021 | Non-covered Recipient Entity Associated Clinicians of East Texas PLLC | A PHASE 3 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN HEALTHY INFANTS | No dispute reported | 06/30/2026 | 832848111 |
| Principal investigator 1 | PFIZER INC. | $802.49 | 09/21/2021 | Non-covered Recipient Entity DCOL Center for Clinical Rsrch | A PHASE 3 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN HEALTHY INFANTS | No dispute reported | 06/30/2026 | 832526209 |
| Principal investigator 1 | PFIZER INC. | $1,417.20 | 09/20/2021 | Non-covered Recipient Entity DCOL Center for Clinical Rsrch | A PHASE 3 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN HEALTHY INFANTS | No dispute reported | 06/30/2026 | 832525111 |
| Principal investigator 1 | PFIZER INC. | $802.49 | 09/13/2021 | Non-covered Recipient Entity DCOL Center for Clinical Rsrch | A PHASE 3 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN HEALTHY INFANTS | No dispute reported | 06/30/2026 | 832525265 |
| Principal investigator 1 | PFIZER INC. | $1,417.20 | 09/13/2021 | Non-covered Recipient Entity DCOL Center for Clinical Rsrch | A PHASE 3 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN HEALTHY INFANTS | No dispute reported | 06/30/2026 | 832526019 |
| Principal investigator 1 | PFIZER INC. | $1,054.11 | 09/04/2021 | Non-covered Recipient Entity Associated Clinicians of East Texas PLLC | A PHASE 3 RANDOMIZED DOUBLEBLINDED PLACEBOCONTROLLED TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF A RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN INFANTS BORN TO WOMEN VACCINATED DURING PREGNANCY | No dispute reported | 06/30/2026 | 832801259 |
| Principal investigator 1 | PFIZER INC. | $5,730.20 | 08/21/2021 | Non-covered Recipient Entity Associated Clinicians of East Texas PLLC | A PHASE 3 RANDOMIZED DOUBLEBLINDED PLACEBOCONTROLLED TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF A RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN INFANTS BORN TO WOMEN VACCINATED DURING PREGNANCY | No dispute reported | 06/30/2026 | 832733045 |
| Principal investigator 1 | PFIZER INC. | $3,273.14 | 08/21/2021 | Non-covered Recipient Entity Associated Clinicians of East Texas PLLC | A PHASE 3 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN HEALTHY INFANTS | No dispute reported | 06/30/2026 | 832881953 |
| Principal investigator 1 | PFIZER INC. | $29,653.70 | 08/06/2021 | Non-covered Recipient Entity Associated Clinicians of East Texas PLLC | A PHASE 3 RANDOMIZED DOUBLEBLINDED PLACEBOCONTROLLED TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF A RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN INFANTS BORN TO WOMEN VACCINATED DURING PREGNANCY | No dispute reported | 06/30/2026 | 832732941 |
| Principal investigator 1 | PFIZER INC. | $1,537.90 | 08/06/2021 | Non-covered Recipient Entity Associated Clinicians of East Texas PLLC | A PHASE 3 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN HEALTHY INFANTS | No dispute reported | 06/30/2026 | 832897829 |
| Principal investigator 1 | SANOFI PASTEUR INC. | $12,750.00 | 08/04/2021 | Non-covered Recipient Entity Associated Clinicians Of East Texas PLLC Dcol Center For Clinical Research | PSK0008 Safety and Immunogenicity of a Pneumococcal Conjugate Vaccine (PCV) when Administered Concomitantly with Routine Pediatric Vaccines in Healthy Toddlers and Infants | No dispute reported | 06/30/2026 | 838358434 |
| Principal investigator 1 | PFIZER INC. | $4,361.76 | 07/21/2021 | Non-covered Recipient Entity Associated Clinicians of East Texas PLLC | A PHASE 3 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN HEALTHY INFANTS | No dispute reported | 06/30/2026 | 832829163 |
| Principal investigator 1 | PFIZER INC. | $3,270.15 | 07/20/2021 | Non-covered Recipient Entity Associated Clinicians of East Texas PLLC | A PHASE 3 RANDOMIZED DOUBLEBLINDED PLACEBOCONTROLLED TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF A RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN INFANTS BORN TO WOMEN VACCINATED DURING PREGNANCY | No dispute reported | 06/30/2026 | 832883217 |
| Principal investigator 1 | PFIZER INC. | $10.82 | 07/06/2021 | Non-covered Recipient Entity DCOL CTR for Clin Research | A PHASE 3 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN HEALTHY INFANTS | No dispute reported | 06/30/2026 | 832578425 |
| Principal investigator 1 | PFIZER INC. | $2,056.73 | 06/29/2021 | Non-covered Recipient Entity Associated Clinicians of East Texas PLLC | A PHASE 3 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN HEALTHY INFANTS | No dispute reported | 06/30/2026 | 832886143 |
| Principal investigator 1 | PFIZER INC. | $8,600.26 | 06/23/2021 | Non-covered Recipient Entity Associated Clinicians of East Texas PLLC | A PHASE 3 RANDOMIZED DOUBLEBLINDED PLACEBOCONTROLLED TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF A RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN INFANTS BORN TO WOMEN VACCINATED DURING PREGNANCY | No dispute reported | 06/30/2026 | 832875023 |
| Principal investigator 1 | PFIZER INC. | $350.00 | 06/16/2021 | Non-covered Recipient Entity Associated Clinicians of East Texas PLLC | A PHASE 2B RANDOMIZED PLACEBOCONTROLLED OBSERVERBLINDED TRIAL TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A RESPIRATORY SYNCYTIAL VIRUS RSV VACCINE IN PREGNANT WOMEN 18 THROUGH 49 YEARS OF AGE AND THEIR INFANTS | No dispute reported | 06/30/2026 | 832714125 |
| Principal investigator 1 | PFIZER INC. | $2,306.85 | 06/09/2021 | Non-covered Recipient Entity Associated Clinicians of East Texas PLLC | A PHASE 3 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN HEALTHY INFANTS | No dispute reported | 06/30/2026 | 832793923 |
| Principal investigator 1 | PFIZER INC. | $350.00 | 06/05/2021 | Non-covered Recipient Entity Associated Clinicians of East Texas PLLC | A PHASE 3 RANDOMIZED DOUBLEBLINDED PLACEBOCONTROLLED TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF A RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN INFANTS BORN TO WOMEN VACCINATED DURING PREGNANCY | No dispute reported | 06/30/2026 | 832801249 |
| Principal investigator 1 | PFIZER INC. | $1,500.00 | 06/05/2021 | Non-covered Recipient Entity Associated Clinicians of East Texas PLLC | A PHASE 2B RANDOMIZED PLACEBOCONTROLLED OBSERVERBLINDED TRIAL TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A RESPIRATORY SYNCYTIAL VIRUS RSV VACCINE IN PREGNANT WOMEN 18 THROUGH 49 YEARS OF AGE AND THEIR INFANTS | No dispute reported | 06/30/2026 | 832815033 |
| Principal investigator 1 | PFIZER INC. | $258.90 | 06/02/2021 | Non-covered Recipient Entity DCOL CTR for Clin Research | A PHASE 3 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN HEALTHY INFANTS | No dispute reported | 06/30/2026 | 832920035 |
| Principal investigator 1 | PFIZER INC. | $802.49 | 05/26/2021 | Non-covered Recipient Entity DCOL Center for Clinical Rsrch | A PHASE 3 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN HEALTHY INFANTS | No dispute reported | 06/30/2026 | 832614339 |
| Principal investigator 1 | PFIZER INC. | $1,417.20 | 05/26/2021 | Non-covered Recipient Entity DCOL Center for Clinical Rsrch | A PHASE 3 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN HEALTHY INFANTS | No dispute reported | 06/30/2026 | 832614357 |
| Principal investigator 1 | PFIZER INC. | $21.64 | 05/24/2021 | Non-covered Recipient Entity DCOL CTR for Clin Research | A PHASE 3 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN HEALTHY INFANTS | No dispute reported | 06/30/2026 | 832776115 |
| Principal investigator 1 | PFIZER INC. | $2,856.00 | 05/21/2021 | Non-covered Recipient Entity Associated Clinicians of East Texas PLLC | A PHASE 3 RANDOMIZED DOUBLEBLINDED PLACEBOCONTROLLED TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF A RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN INFANTS BORN TO WOMEN VACCINATED DURING PREGNANCY | No dispute reported | 06/30/2026 | 832772749 |
| Principal investigator 1 | PFIZER INC. | $4,004.19 | 05/21/2021 | Non-covered Recipient Entity Associated Clinicians of East Texas PLLC | A PHASE 3 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN HEALTHY INFANTS | No dispute reported | 06/30/2026 | 832826283 |
| Principal investigator 1 | PFIZER INC. | $10.82 | 05/10/2021 | Non-covered Recipient Entity DCOL CTR for Clin Research | A PHASE 3 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN HEALTHY INFANTS | No dispute reported | 06/30/2026 | 832758159 |
| Principal investigator 1 | PFIZER INC. | $3,140.87 | 05/07/2021 | Non-covered Recipient Entity Associated Clinicians of East Texas PLLC | A PHASE 3 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN HEALTHY INFANTS | No dispute reported | 06/30/2026 | 832767491 |
| Principal investigator 1 | PFIZER INC. | $345.20 | 04/29/2021 | Non-covered Recipient Entity DCOL CTR for Clin Research | A PHASE 3 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN HEALTHY INFANTS | No dispute reported | 06/30/2026 | 832761609 |
| Principal investigator 1 | PFIZER INC. | $43.28 | 04/29/2021 | Non-covered Recipient Entity DCOL CTR for Clin Research | A PHASE 3 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN HEALTHY INFANTS | No dispute reported | 06/30/2026 | 832775923 |
| Principal investigator 1 | PFIZER INC. | $3,270.15 | 04/24/2021 | Non-covered Recipient Entity Associated Clinicians of East Texas PLLC | A PHASE 3 RANDOMIZED DOUBLEBLINDED PLACEBOCONTROLLED TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF A RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN INFANTS BORN TO WOMEN VACCINATED DURING PREGNANCY | No dispute reported | 06/30/2026 | 832837151 |
| Principal investigator 1 | PFIZER INC. | $2,974.44 | 04/21/2021 | Non-covered Recipient Entity Associated Clinicians of East Texas PLLC | A PHASE 3 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN HEALTHY INFANTS | No dispute reported | 06/30/2026 | 832874345 |
| Principal investigator 1 | PFIZER INC. | $1,510.59 | 04/09/2021 | Non-covered Recipient Entity Associated Clinicians of East Texas PLLC | A PHASE 3 RANDOMIZED DOUBLEBLINDED PLACEBOCONTROLLED TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF A RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN INFANTS BORN TO WOMEN VACCINATED DURING PREGNANCY | No dispute reported | 06/30/2026 | 832768715 |
| Principal investigator 1 | PFIZER INC. | $200.00 | 04/09/2021 | Non-covered Recipient Entity Associated Clinicians of East Texas PLLC | A PHASE 2B RANDOMIZED PLACEBOCONTROLLED OBSERVERBLINDED TRIAL TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A RESPIRATORY SYNCYTIAL VIRUS RSV VACCINE IN PREGNANT WOMEN 18 THROUGH 49 YEARS OF AGE AND THEIR INFANTS | No dispute reported | 06/30/2026 | 832794257 |
| Principal investigator 1 | PFIZER INC. | $5,764.55 | 03/24/2021 | Non-covered Recipient Entity Associated Clinicians of East Texas PLLC | A PHASE 3 RANDOMIZED DOUBLEBLINDED PLACEBOCONTROLLED TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF A RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN INFANTS BORN TO WOMEN VACCINATED DURING PREGNANCY | No dispute reported | 06/30/2026 | 832849943 |
| Principal investigator 1 | PFIZER INC. | $1,942.88 | 03/24/2021 | Non-covered Recipient Entity Associated Clinicians of East Texas PLLC | A PHASE 2B RANDOMIZED PLACEBOCONTROLLED OBSERVERBLINDED TRIAL TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A RESPIRATORY SYNCYTIAL VIRUS RSV VACCINE IN PREGNANT WOMEN 18 THROUGH 49 YEARS OF AGE AND THEIR INFANTS | No dispute reported | 06/30/2026 | 832883207 |
| Principal investigator 1 | PFIZER INC. | $54.10 | 03/15/2021 | Non-covered Recipient Entity DCOL CTR for Clin Research | A PHASE 3 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN HEALTHY INFANTS | No dispute reported | 06/30/2026 | 832729013 |
| Principal investigator 1 | PFIZER INC. | $431.50 | 03/15/2021 | Non-covered Recipient Entity DCOL CTR for Clin Research | A PHASE 3 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN HEALTHY INFANTS | No dispute reported | 06/30/2026 | 832758167 |
| Principal investigator 1 | PFIZER INC. | $2,658.52 | 03/13/2021 | Non-covered Recipient Entity Associated Clinicians of East Texas PLLC | A PHASE 2B RANDOMIZED PLACEBOCONTROLLED OBSERVERBLINDED TRIAL TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A RESPIRATORY SYNCYTIAL VIRUS RSV VACCINE IN PREGNANT WOMEN 18 THROUGH 49 YEARS OF AGE AND THEIR INFANTS | No dispute reported | 06/30/2026 | 832873465 |
| Principal investigator 1 | PFIZER INC. | $1,510.59 | 03/05/2021 | Non-covered Recipient Entity Associated Clinicians of East Texas PLLC | A PHASE 3 RANDOMIZED DOUBLEBLINDED PLACEBOCONTROLLED TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF A RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN INFANTS BORN TO WOMEN VACCINATED DURING PREGNANCY | No dispute reported | 06/30/2026 | 832800325 |
| Principal investigator 1 | PFIZER INC. | $1,070.32 | 02/24/2021 | Non-covered Recipient Entity Associated Clinicians of East Texas PLLC | A PHASE 2B RANDOMIZED PLACEBOCONTROLLED OBSERVERBLINDED TRIAL TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A RESPIRATORY SYNCYTIAL VIRUS RSV VACCINE IN PREGNANT WOMEN 18 THROUGH 49 YEARS OF AGE AND THEIR INFANTS | No dispute reported | 06/30/2026 | 832757327 |
| Principal investigator 1 | PFIZER INC. | $11,193.07 | 02/23/2021 | Non-covered Recipient Entity Associated Clinicians of East Texas PLLC | A PHASE 3 RANDOMIZED DOUBLEBLINDED PLACEBOCONTROLLED TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF A RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN INFANTS BORN TO WOMEN VACCINATED DURING PREGNANCY | No dispute reported | 06/30/2026 | 832739289 |
| Principal investigator 1 | PFIZER INC. | $587.28 | 02/05/2021 | Non-covered Recipient Entity Associated Clinicians of East Texas PLLC | A PHASE 2B RANDOMIZED PLACEBOCONTROLLED OBSERVERBLINDED TRIAL TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A RESPIRATORY SYNCYTIAL VIRUS RSV VACCINE IN PREGNANT WOMEN 18 THROUGH 49 YEARS OF AGE AND THEIR INFANTS | No dispute reported | 06/30/2026 | 832840965 |
| Principal investigator 1 | PFIZER INC. | $1,054.11 | 02/05/2021 | Non-covered Recipient Entity Associated Clinicians of East Texas PLLC | A PHASE 3 RANDOMIZED DOUBLEBLINDED PLACEBOCONTROLLED TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF A RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN INFANTS BORN TO WOMEN VACCINATED DURING PREGNANCY | No dispute reported | 06/30/2026 | 832901137 |
| Principal investigator 1 | PFIZER INC. | $1,054.11 | 01/16/2021 | Non-covered Recipient Entity Associated Clinicians of East Texas PLLC | A PHASE 3 RANDOMIZED DOUBLEBLINDED PLACEBOCONTROLLED TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF A RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN INFANTS BORN TO WOMEN VACCINATED DURING PREGNANCY | No dispute reported | 06/30/2026 | 832847749 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $7,209.10 | 01/15/2021 | Non-covered Recipient Entity ASSOCIATED CLINICIANS OF EAST TEXAS | A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of MEDI8897, a Monoclonal Antibody With an Extended Half-life Against Respiratory Syncytial Virus, in Healthy Late Preterm and Term Infants (MELODY) | No dispute reported | 06/30/2026 | 826492779 |
| Principal investigator 1 | PFIZER INC. | $1,230.11 | 01/09/2021 | Non-covered Recipient Entity Associated Clinicians of East Texas PLLC | A PHASE 3 RANDOMIZED DOUBLEBLINDED PLACEBOCONTROLLED TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF A RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN INFANTS BORN TO WOMEN VACCINATED DURING PREGNANCY | No dispute reported | 06/30/2026 | 832692951 |
| Principal investigator 1 | PFIZER INC. | $2,433.60 | 01/09/2021 | Non-covered Recipient Entity Associated Clinicians of East Texas PLLC | A PHASE 2B RANDOMIZED PLACEBOCONTROLLED OBSERVERBLINDED TRIAL TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A RESPIRATORY SYNCYTIAL VIRUS RSV VACCINE IN PREGNANT WOMEN 18 THROUGH 49 YEARS OF AGE AND THEIR INFANTS | No dispute reported | 06/30/2026 | 832915311 |
| Principal investigator 1 | PFIZER INC. | $345.20 | 01/05/2021 | Non-covered Recipient Entity DCOL CTR for Clin Research | A PHASE 3 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN HEALTHY INFANTS | No dispute reported | 06/30/2026 | 832909851 |
| Principal investigator 1 | PFIZER INC. | $43.28 | 01/05/2021 | Non-covered Recipient Entity DCOL CTR for Clin Research | A PHASE 3 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN HEALTHY INFANTS | No dispute reported | 06/30/2026 | 832922455 |